格隆汇10月24日丨亚宝药业(600351.SH)公布三季度报告，前三季营业收入17亿元，同比下降19.46%， 归属于上市公司股东的净利润2.15亿元，同比下降8.44%，归属于上市公司股东的扣除非经常性损益的 净利润1.97亿元，同比下降9.03%。 ...

亚宝药业公告，第三季度营收为5.69亿元，同比下降16.01%；净利润为4069.71万元，同比下降 26.22%。前三季度营收为17.09亿元，同比下降19.46%；净利润为2.15亿元，同比下降8.44%。 ...

| 交易日期 | | 证券代码 | 成交价(元) 成交金额(万元) 成交量(*) 买入营业部 | | | 卖出营业部 | 是否为专场 | | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-10-23 | 亚宝药业 | 600351 | 6.83 273.2 | 40 | 机构专用 | 去夢髮發驚拿舞蹈 | Ka | 10月23日，亚宝药业大宗交易成交40万股，成交额273.2万元，占当日总成交额的3.19%，成交价6.83 元，较市场收盘价6.83元持平。 ...

Core Points - The company announced that its wholly-owned subsidiary, Beijing Yabao Biological Pharmaceutical Co., Ltd., has received the drug registration certificate for Sitagliptin Metformin Extended-Release Tablets from the National Medical Products Administration [1] Group 1 - The drug registration certificate has the number 2025S03027 [1]

Group 1 - Harbin Air Conditioning plans to transfer 40% equity of its subsidiary, Harbin Fushanchuan Biotechnology Development Co., Ltd. The subsidiary reported a net profit of -16.0963 million yuan for 2024, which is 218.83% of the previous year's net profit absolute value [1] - Xinhua Insurance expects a net profit of 29.986 billion to 34.122 billion yuan for the first three quarters of 2025, representing a year-on-year growth of 45% to 65% [1][2] - Gansu Energy anticipates a net profit of 1.55 billion to 1.6 billion yuan for the first three quarters of 2025, reflecting a year-on-year increase of 11.86% to 15.47% [2][3] Group 2 - Dongfang Tower forecasts a net profit of 750 million to 900 million yuan for the first three quarters of 2025, indicating a year-on-year growth of 60.83% to 93% [4] - Meili Eco announced that its subsidiary won a bid for an EPC project worth 2.375 billion yuan [6] - Bohai Chemical's wholly-owned subsidiary will undergo routine maintenance for its 600,000 tons/year PDH unit, expected to last about 30 days [8] Group 3 - Qin Port Co. reported a total throughput of 317.02 million tons for the first nine months of 2025, a year-on-year increase of 5.56% [10] - Jianglong Shipbuilding won a bid for a 72.99 million yuan fishery enforcement vessel project, accounting for 4.22% of its 2024 audited revenue [11] - Longyuan Technology expects a net profit of 35 million to 40 million yuan for the first three quarters of 2025, representing a year-on-year increase of 50.11% to 71.55% [12] Group 4 - Naipu Mining anticipates a net profit of 61 million to 66 million yuan for the first three quarters of 2025, reflecting a year-on-year decline of 45.16% to 49.32% [14] - Jinggong Steel Structure reported a cumulative contract amount of 17.98 billion yuan for the first nine months of 2025, a year-on-year increase of 4.8% [15][16] - Shenzhen Gas reported a net profit of 918 million yuan for the first three quarters of 2025, a year-on-year decrease of 13.08% [17] Group 5 - Yabao Pharmaceutical's subsidiary received a drug registration certificate for a new diabetes medication [18] - Shaanxi Coal's coal production in September was 14.56 million tons, a year-on-year increase of 5.34% [20] - Sifang New Materials reported a 15.94% year-on-year decline in concrete production for the first three quarters [22] Group 6 - Nanjing Foods reported a consolidated revenue of 276 million yuan in September, a slight increase of 0.0016% year-on-year [23] - Pulaike received a new veterinary drug registration certificate for a flea and tick treatment [24] - Zhucheng Technology received a cash dividend of 15 million yuan from its subsidiary [25] Group 7 - David Medical's subsidiary received a medical device registration certificate for a portable electronic endoscope image processor [26] - Zhongtong Bus reported a 36.88% year-on-year increase in sales in September, totaling 1,106 units [27] - Xiantan Co. reported a 11.95% year-on-year increase in chicken sales revenue in September [28] Group 8 - Bojun Technology expects a net profit of 552 million to 662 million yuan for the first three quarters of 2025, a year-on-year increase of 50% to 80% [30] - Haishi Pharmaceutical's innovative pain relief drug clinical trial application has been accepted [31] - Lingxiao Pump Industry used 80 million yuan of idle funds to purchase financial products [32] Group 9 - Qiangda Circuit's subsidiary completed business registration changes to expand its operational scope [33] - *ST Tianyu's controlling shareholder applied for bankruptcy liquidation due to severe financial difficulties [34] - Baolidi's shareholder plans to reduce holdings by up to 1 million shares [36] Group 10 - Zijin Mining completed the acquisition of Kazakhstan's Raygorodok gold mine, controlling 100% of its rights [44] - Zhonggang Luoyang's indirect controlling shareholder completed a capital increase, raising registered capital from approximately 26.666 billion yuan to 44.824 billion yuan [46] - Jinyu Jidong's director resigned due to work adjustments [47]

Core Viewpoint - Company YaBao Pharmaceutical (600351.SH) has received approval from the National Medical Products Administration for the registration of its product, Sitagliptin Metformin Extended-Release Tablets, which is intended for adult patients with type 2 diabetes [1] Group 1: Product Approval - YaBao's wholly-owned subsidiary, Beijing YaBao Biopharmaceutical Co., Ltd., has been granted the drug registration certificate for Sitagliptin Metformin Extended-Release Tablets (Certificate No: 2025S03027) [1] - The product is designed for adults currently undergoing treatment with a combination of Sitagliptin and Metformin Extended-Release Tablets [1] Group 2: Market Context - Sitagliptin Metformin Extended-Release Tablets were developed by Merck Sharp & Dohme and were approved for sale in the United States in 2012 under the brand name JANUMETXR® [1] - According to data from Minet, the total sales amount for Sitagliptin Metformin Tablets (I), Sitagliptin Metformin Tablets (II), and Sitagliptin Metformin Extended-Release Tablets in China is approximately 921 million RMB for 2024 [1] - Of this total, sales in public hospitals account for 721 million RMB, while retail pharmacies contribute 200 million RMB [1]

Core Viewpoint - The company, Yabao Pharmaceutical (600351.SH), announced that its wholly-owned subsidiary, Beijing Yabao Biopharmaceutical Co., Ltd., has received the drug registration certificate for Sitagliptin Metformin Extended-Release Tablets from the National Medical Products Administration, indicating a significant regulatory approval for a new diabetes treatment [1]. Group 1 - The drug Sitagliptin Metformin Extended-Release Tablets is intended for adult patients with type 2 diabetes who are currently receiving a combination treatment of Sitagliptin and Metformin Extended-Release Tablets [1].

证券代码：600351 证券简称：亚宝药业 公告编号：2025-038 亚宝药业集团股份有限公司 关于全资子公司取得药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，亚宝药业集团股份有限公司（以下简称"公司"）全资子公司北京亚 宝生物药业有限公司（以下简称"亚宝生物"）收到了国家药品监督管理局（以 下简称"国家药监局"）核准签发的西格列汀二甲双胍缓释片《药品注册证书》 （证书编号：2025S03027）。现将相关情况公告如下： 一、药品注册证书主要内容 1、药品名称：西格列汀二甲双胍缓释片 2、剂型：片剂 3、规格：磷酸西格列汀 100mg（按 C₁₆H₁₅F₆N₅O 计）与盐酸二甲双胍 1000mg 4、包装规格：30 片/瓶 5、注册分类：化学药品 3 类 8、药品批准文号：国药准字 H20255599 9、审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查， 本品符合药品注册的有关要求，批准注册，发给药品注册证书。 二、药品的其他情况 西格列汀二甲双胍缓释片适用于正在接受西格列汀和二甲双 ...

Core Viewpoint - The announcement highlights that the company's wholly-owned subsidiary, Beijing Yabao Biological Pharmaceutical Co., Ltd., has received the drug registration certificate for Sitagliptin Metformin Extended-Release Tablets from the National Medical Products Administration, indicating a significant milestone for the company in the diabetes treatment market [1] Group 1: Product Approval - The Sitagliptin Metformin Extended-Release Tablets are approved for use in adult patients with type 2 diabetes [1] - The drug was developed by Merck Sharp Dohme and was approved for sale in the United States in 2012 [1] - The expected sales amount for the product in China in 2024 is approximately 921 million RMB [1] Group 2: Market Context - A total of 11 companies have received the registration approval for this drug in China [1] - The company has invested approximately 15.3284 million RMB in research and development for this product [1]

Core Viewpoint - Yabao Pharmaceutical (600351.SH) has repurchased a total of 6 million shares, representing 0.86% of the company's total share capital, with a total expenditure of RMB 38.878 million as of September 30, 2025 [1] Summary by Category - **Share Repurchase Details** - The company has conducted share repurchases through centralized bidding [1] - The highest transaction price was RMB 6.65 per share, while the lowest was RMB 6.30 per share [1] - The total amount paid for the repurchased shares is RMB 38.878 million, excluding transaction fees [1]